Discriminating between mild cognitive impairment and Alzheimer's diseaseValidation of early Alzheimer's biomarkers by combining advanced imaging and in vitro diagnostic techniques

  1. Aramburu Nuñez, Marta
Dirixida por:
  1. Tomas Sobrino Moreiras Director
  2. José Antonio Castillo Sánchez Director

Universidade de defensa: Universidade de Santiago de Compostela

Fecha de defensa: 16 de novembro de 2023

Tribunal:
  1. Mikko Hiltunen Presidente/a
  2. Pablo Aguiar Fernández Secretario
  3. José Miguel Laínez Andrés Vogal
Departamento:
  1. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina

Tipo: Tese

Teseo: 825080 DIALNET lock_openMINERVA editor

Resumo

Alzheimer’s disease (AD) is the leading cause of dementia, implying a progressive decline of cognitive performance and limitation of social activities. In this scenario, in parallel to current research of novel treatments, it is imperative to develop new strategies for an earlier diagnosis of AD. This study has focused on the importance of different isoforms of the Tau protein involved in early pathophysiological processes of AD. Specifically, two new monoclonal antibodies (mAb) against phosphorylated tau (p-Tau) and acetylated tau (ac-Tau) have been produced, with which a clinical immunodiagnostic kit and a preclinical radiotracer for PET 89-Zirconium (89Zr)-pTau mAb have been developed for diagnostic purposes. In addition, a preclinical proof of concept of immunotherapy with p-Tau antibody has been also carried out.